By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tarsa Therapeutics 

Philadelphia  Pennsylvania    U.S.A.
Phone: n/a Fax: n/a



Start Up

Company News
Tarsa Therapeutics Secures $10 Million, Adds Industry Veteran As A Director 8/13/2014 6:39:37 AM
Tarsa Therapeutics Reels In $7 Million To Prepare For Filing NDA For Ostora 5/29/2014 7:26:05 AM
Tarsa Therapeutics Presents Meta-Analysis at ASBMR 2013 Showing Calcitonin Does Not Appear to be Associated With Increased Risk of Cancer 10/7/2013 6:57:36 AM
Tarsa Therapeutics Reports Positive Results From Phase II Trial of Its Oral Calcitonin in Prevention of Post-Menopausal Osteoporosis 10/16/2012 9:27:42 AM
Tarsa Therapeutics' Drug Successful in Prevention of Post-Menopausal Osteoporosis 10/16/2012 6:54:54 AM
Tarsa Therapeutics to Assist Therapicon in Its Challenge to CHMP's Recommendation to Limit Use of Calcitonin 10/12/2012 10:54:55 AM
Tarsa Therapeutics Signs Commercial Supply Agreement for its Ostora(TM) Oral Calcitonin Product With QS Pharma 3/21/2012 10:44:03 AM
Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORAâ„¢ Oral Calcitonin 3/16/2012 6:27:25 AM
Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA(TM) Oral Calcitonin 12/13/2011 11:11:52 AM
Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial 9/19/2011 10:48:27 AM